Reticulohistiocytoma Treatments
Find Reticulohistiocytoma Treatments
Medications for Reticulohistiocytoma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Reticulohistiocytoma.
Found 3 Approved Drugs for Reticulohistiocytoma
Zelboraf
Generic Name
Vemurafenib
Zelboraf
Generic Name
Vemurafenib
Form: Tablet
Method of administration: Oral
FDA approval date: August 17, 2011
Classification: Kinase Inhibitor
ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Aqneursa
Generic Name
Levacetylleucine
Aqneursa
Generic Name
Levacetylleucine
Form: Granule
Method of administration: Oral
FDA approval date: September 24, 2024
AQNEURSA™ is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. AQNEURSA is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. ( 1 )
Xenpozyme
Generic Name
Olipudase Alfa-Rpcp
Xenpozyme
Generic Name
Olipudase Alfa-Rpcp
Form: Injection
Method of administration: Intravenous
FDA approval date: August 29, 2022
XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. XENPOZYME is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. ( 1 )
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances